April 12, 2017

Chinese Pharma Industry Leader Mingde Yu to Keynote Shanghai Conference

Mr. Mingde Yu Chairman of the China Pharmaceutical Enterprises Administrative Association will be a keynote speaker at the SEBP 2017 Shanghai China. The conference, which is in it’s 5th year brings a select group of European companies to China to foster partnerships. Mr. Yu heads an organization comprised of nearly 800 […]
April 12, 2017

New Drugs in Opiate Addiction Battle

The New York City Police Department reported a startling statistic last week: a 38% increase in fatal opioid overdoses in the city last year. Approximately 1,300 fatalities – more than homicide (335) and traffic collision (220) deaths combined – were recorded, mainly as a result of heroin and painkiller overdoses. […]
April 12, 2017

The Sentinel Breakthroughs in Health & Technology | Trends in Finance | April 8th, 2017

IN THIS ISSUE: FEATURE: New Drugs in Opiate Addiction Battle. As the overdose statistics continue to rise the need for innovative ways to deal with the Opiate epidemic. Can new drugs be the answer? A look at three promising advances. COMPANY NEWS: OncoSec Advances IL 12 Immunotherpy for Melanoma Interpace […]
April 11, 2017

BioCentury Holds 24th Annual Future Leaders Conference

Biocentury is celebrating 25 years in business having hosted last week their 24th Future Leaders conference which is the longest running independent investment conference serving the biopharma industry; helping showcase biotech companies independently vetted by BioCentury, developing best-in-class products and discovery platforms in important disease areas. The 2017 Class follows this theme, […]
April 11, 2017

Med Industry Association Joins MedTech Conference

The Advanced Medical Technology Association (AdvaMed) recently announced a partnership with the Medical Device Manufacturers Association (MDMA) to jointly promote The MedTech Conference, formerly AdvaMed 2017. The MedTech Conference will be held September 25-27 in San Jose, CA.  After record-setting attendance last year in Minneapolis, AdvaMed hopes to continue the […]
April 11, 2017

SeaSpine’s Advanced Spinal Surgery Technologies

SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons […]
April 11, 2017

Leap Therapeutics’ Antibodies to Treat Cancer

Leap Therapeutics, Inc. (LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, recently reported financial results for the year ended December 31, 2016 and top-line progression-free survival (PFS) data. Earlier this year, Leap merged with Macrocure Ltd. and became listed on NASDAQ. The company’s most advanced clinical candidate, DKN-01, is a humanized monoclonal […]
April 11, 2017

Genprex’s 21st Century Gene Therapies for Cancer

Genprex is a clinical-stage biopharmaceutical company developing targeted molecular therapies for cancer. The company is developing molecular therapies that control universal cancer pathways to unlock the unrealized potential of targeted cancer therapies, such as tyrosine kinase inhibitory drugs (TKIs). Genprex’s tumor suppression technologies are pan-kinase inhibitors that work to induce apoptosis (programmed […]
April 11, 2017

Sensori AB’s Medical Devices for the Human Senses

Sensori AB is a company investing in innovative products that make life easier for major disease groups worldwide in the ear, nose and throat area while providing an economic value by reducing healthcare consumption and reduce the antibiotics and other drugs consumption. The company will conduct research, development, manufacture, marketing and […]
April 11, 2017

David Buzkin on Microcaps and the IPOs

David Bukzin is the national partner -in charge of Marcum’s SEC practice with a focus on securities underwritings for emerging growth companies he organized the Marcum Microcap conference in 2010 to facilitate development for  smaller size public companies under $500 market caps. He discusses the origins and mission of the […]
April 11, 2017

Glynn Wilson – CEO of TapImmune on Vaccines for Cancer

Immunotherapy is the future of cancer treatment and TapImmune has been leading the charge. CEO Glynn Wilson discusses the advances made in the ovarian and breast cancer. The company is taking a vaccine approach to reduce recurrence of cancer and to improve progression free survival and in some cases to […]
April 11, 2017

ITUS Closes $4.7 Million Rights Offering

\ITUS Corporation (“ITUS”) (NASDAQ: ITUS), recently announced that its rights offering of common shares closed, raising gross proceeds of approximately $4.7 million before payment of dealer manager fee and other expenses, through the issuance of 1,989,207 shares of common stock. Robert Berman, ITUS’s President and CEO, stated, “Proceeds from the […]
April 11, 2017

CymaBay Announces the Retirement of CEO Van Wart

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company developing therapies for specialty and orphan diseases announced that Harold Van Wart, Ph.D., will retire as President and Chief Executive Officer. CFO Sujal Shah, will become interim President and Chief Executive Officer. “It has been my privilege to work with such an excellent […]
April 11, 2017

Interpace Reports Year End Results

Interpace Diagnostics Group, Inc., a company that provides molecular diagnostic tests and pathology services, announced year end financial results, as well as recent accomplishments. “2016 was a breakout year as we delivered strong revenue growth, significant cost reductions and right sizing as we completed our transition to a fully-integrated, commercially based molecular […]
April 11, 2017

OncoSec Advances IL 12 Immunotherapy for Melanoma

OncoSec Medical Incorporated (NASDAQ: ONCS) was recently granted FDA Fast Track designation to address the large population of non-responders to the current leading checkpoint inhibitor therapies for stage 4 melanoma. The leading drugs in this $5 billion market are marketed under the names, Opdivo and Keytruda.   An estimated 70% […]
March 28, 2017

Neurotrope: Time to Buy your Lottery Ticket?

Amidst the carnage and failure of failed Alzheimer’s drug trials, there is a small company that is weeks away from Phase 2 results that could change the landscape of this disease. Neurotrope (NTRP) is at the point where some fortunes may be made and possible good news may come for the […]
March 23, 2017


Interested in joining the OneMedNews team? See below for open job opportunities. Journalism/Public Relations freelance writer OneMedNews is looking for a go-getter freelance writer to conduct interviews and write stories for the OneMedNews Sentinel, a biweekly e-newsletter focused on the healthcare and life sciences industry. Must be interested in covering […]
March 12, 2017

The Sentinel Breakthroughs in Health & Technology | Trends in Finance | March 12, 2017

IN THIS ISSUE: FEATURE: The Case for a Healthcare Futures Market Dennis Purcell and his team at Poliwogg outline the prospects and potential to bring stability to the healthcare market through creating a futures exchange, starting with a diabetes index. COMPANY NEWS: Life Care Medical Devices adds prominent industry expert […]
March 11, 2017

China BioVentures to Sponsor SEBP 2017 Conference in Shanghai

China BioVentures will be sponsoring the Sino-Euro Bio Partnering event (SEBP)  and the new Fenglin Biomedical Center in Shanghai, China on May 15th-16th. The SEBP event is an annual conference for international Small and Medium Enterprises (SMEs) to partner with Chinese companies and investors. China BioVentures will be bringing a […]
February 26, 2017

Buzz of Bio 2017 Winners and Finalists

  The 19th annual BIO CEO & Investor Conference is one of the largest investor conferences to highlight both established and emerging publicly traded and select private biotech companies.The conference establishes a platform for institutional investors, industry analysts, and top biotechnology executives to shape the future investment landscape in biotechnology. […]